IRF1 and neoplasm: Recent studies have highlighted that signaling pathways such as BRD4/IRF1 (Hogg et al., 2017), PI3K/AKT, and FAK/Src contribute to PD-L1 upregulation (Wang et al., 2022b), facilitating tumor immune escape.